OSAKA, Japan, November, 24, 2021 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D. ; hereafter “Shionogi”) announced that there are concerns that some research reagent sales companies and their distributors sold a compound which was different from S-217622, an orally administered antiviral drug for COVID-19, as the same as S-217622.
S-217622 is a novel compound with 3CL protease inhibitory activity discovered by Shionogi. It was found that S-217622 was listed in the online catalog of the reagent sales company written together with "YH-53", which was 3CL protease inhibitor. Currently, the description has been deleted.
At this time, Shionogi does not disclose a structure of S-217622 or does not have a sales contract of S-217622 as a research reagent. Please be careful if you accidentally purchased it as a research reagent or if you were confused with YH-53.
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
For Further Information, Contact:
Corporate Communications Department
Shionogi & Co., Ltd.
Contact form: https://www.shionogi.com/global/en/contact.html